HighTower Advisors’s Alimera Sciences ALIM Stock Holding History

HighTower Advisors’s Portfolio ALIM Stock Details ALIM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-25,091	Closed	-$108K	–	4092
2023 Q4	$108K	Buy	+25,091	New	+$84.8K	﹤0.01%	3180

Other funds holding ALIM

Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return

VCIM

Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

ACM

Altium Capital Management New York $42M AUM

Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return

ACM

AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

HighTower Advisors's ALIM Position: Q1 2024 in Review

HighTower Advisors sold out of Alimera Sciences (ALIM) in Q1 2024, closing a stake of 25,091 shares — an estimated $108K sold.

HighTower Advisors first reported a position in ALIM in Q4 2023 and held it in 1 quarter. The position peaked at $108K in Q4 2023. 39 funds tracked by Wall St. Rank hold ALIM as of Q1 2024.

HighTower Advisors reported no remaining Alimera Sciences position as of Q1 2024 after selling out during the quarter.
HighTower Advisors sold 25,091 Alimera Sciences shares in Q1 2024, an estimated $108K.
HighTower Advisors first reported a position in Alimera Sciences in Q4 2023 and held it in 1 quarter.
HighTower Advisors's Alimera Sciences position peaked at $108K in Q4 2023.
39 funds tracked by Wall St. Rank held Alimera Sciences as of Q1 2024.

Based on HighTower Advisors's 13F filing for Q1 2024, filed 6 May 2024.